We have developed a new method for quantifying teicoplanin in complex matrixes, a receptor-antibody sandwich assay (RASA). The method is based on bioselective adsorption of teicoplanin onto microtiter plates coated with albumin-caminocaproyl-o-alanyl-D-alanine, a synthetic analog of its biological target, and reaction with anti-teicoplanin antibodies. The sandwich complexes are detected by incubation with peroxidase-labeled goat antibodies to rabbit lgGs and chromogenic reaction with o-phenylenediamine. The dose-response curve was linear for teicoplanin concentrations in the range from 0 to 0.15 mg/L. We used the assay to measure teicoplanin concentrations in various biological matrixes. Analytical recovery from serum was 99.5%, the interassay CV was 5.1%, and the detection limit was 30 tg/L (P <0.01). Mean analytical recoveries from other biological specimens were 98% from ascitic fluid, 100% from pleuric liquid, 104.8% from prostate homogenate, and 98.5% from bronchial expectorate. receptor assay (si'mt) (3). The latter differs somewhat from conventional methods, being based on the binding of teicoplanin to c-aminocaproyl-r-alanyl-r)-alanine conjugated to bovine serum albumin (BSA-e-Aca-i>Ala-n-Ala), a synthetic biological receptor analog of the bacterial cell-wall target (4) (5) (6) .' Each of these methods presents some advantages and some limitations. For instance, the microbiological assay is not specific for teicoplanin in the presence of other antibiotice, nor it is sufficiently accurate in complex matrixes. The liquid-chromatographic method requires equipment not always available in most clinical laboratories as well as laborious extraction procedures for sample preparation. The srmt presents some advantages in terms of applicability, but it is not always accurate in complex biological matrixes such as bronchial expectorates or skin homogenates.
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high dilutions, and to improve specificity and selectivity, we have developed a new method, a receptor-antibody sandwich assay (RASA), that combines the high selectivity of receptor assays with the specificity of immunoassays. This assay involves a "sandwich" reaction between BSA-e-Aca-1-Ala-DAla, teicoplanin, and anti-teicoplanin antibodies.
Here we describe the RASA and its application in determining teicoplanin in several biological matrixes.
Materials and Methods

Materials
Chemicals. Peroxidase (EC 1.11.1.7)-conjugated specific goat antibodies to rabbit IgGs (H + L) were obtained from Kirkegaard & Perry Laboratories, Gaithersburg, MD 20879; bovine serum albumin (BSA; Cohn Fraction V), 0-phenylenediamine, and polyoxyethylene sorbitan monolaurate ("Tween 20") from Sigma Chemical Co., St. Louis, MO 63178; and bovine serum from Flow Laboratories, McLean, VA 22102.
BSA-c-Aca-n-Ala-u-Ala was prepared as described previously (3) . Antiserum to teicoplanin, supplied by Dr. C. Rurali (Gruppo Lepetit SpA, Milan, Italy), was prepared as follows: teicoplanin conjugated to BSA by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide as cross-linking reagent (7) was used to raise antibodies in New Zealand White rabbits. The teicoplanin-BSA conjugate, 1 g/L in isotonic saline (NaCl 150 mmolfL), was emulsified with an equal volume of Freund's complete adjuvant and injected (1.5 mL) subcutaneously. Boosterinjections were given at three-week intervals for three months with 0.5 mL of emulsion. The animals were bled two weeks afterthe last injection and the serum was stored at -20 #{176}C until used.
Teicoplanin, prepared by Gruppo Lepetit SpA, is a mixtureof five closely related compounds of similar polarity, T-A2 complex (formerly called teichomycin A2), and a more polar product T-A3 (10% of the total complex). Vancomycin concentration of BSA-e-Aca-o-Ala-r-Ala.
The wells of the last vertical row of each plate were coated with BSA alone (blank wells). We storedthe coated plates in plastic bags at 4#{176}Cuntiluse.
Assay Procedure
RASA of glycopeptide antibiotics.
We Quantitative detection of teicoplanin in complex matrixes. We used only the portion of the teicoplanin dose-response curve that was linear when plotted on graph paper, i.e., the range between 0 to 0.15 mg/L, to detect teicoplanin in serum, ascitic fluid, skin homogenate, bronchial expectorate, pleural liquid, and prostate homogenate. Teicoplanin standard solutions were prepared at two different concentrations (75 and 150 ng/mL) in PBS-BT containing 200 mL of bovine serum per liter (PBS-BTS). We assayed the various types of samples at two different dilutions, expected to provide concentrations of 150 and 75 ng/mL, using PBS-BTS as diluent. In all we analyzed three samples on each coated plate, ifiling the wells as follows: 64 wells (columns 3 to 10) with standards and diluted samples according to the Latin square design; 24 wells (columns 1,2, and 11) with PBS-BTS ("zero standard"); and eight wells, coated with BSA but without BSA-c-Aca-n-Ala-o-Ala (blank wells, column 12), with samples to evaluate nonspecific binding. Successive RASA steps were carried out as described above, with PBS-BTS as the antisera diluent. Teicoplanin concentrations were calculated according to the "slope ratio" method (9).
Results
Assay Specificity
RASA of teicoplanin.
We obtained a dose-response curve in the teicoplanin concentration range of 0.004 to 0.4 mg/L, indicating that the sandwich complex between BSA-c-Aca-D-Ala-D-Ala, teicoplanin, and anti-teicoplanin antibodies was formed in spite of the low molecular mass of the antibiotic (Figure 1) . Moreover, we observed no binding of chemically and biologically related to teicoplanin, such as  vancomycin, A-41030, A-47934, A-35512-B, avoparcin, actaplanin, and ristocetin (5) . There was no response in the concentration range between 0.001 mg/L and 100 mg/L for all the antibiotics tested. We conclude that the double interaction of teicoplanin with BSA-#{128}-Aca-n-Ala-n-Ala and the antibodies is highly specific for teicoplanin. However, when we assayed teicoplanin solutions in the presence of variousconcentrations of vancomycin, we found that recoveries of teicoplanin were lower than expected (data not shown). We attribute this to the fact that all glycopeptide antibiotics react with BSA-#{128}-Aca-n-Ala-o-Ala (3), thus reducing the number of binding sites available for teicoplanin. Because similar effects should be expected also with other antibiotics of the same class, RASA cannot be used to determine teicoplanin in the presence of other glycopeptide antibiotics without previous studies of interferences.
Quantitative Detection of Teicoplanin in Complex Matrixes
Calibration curve. We obtained a linear dose-response curve by assaying six teicoplanin solutions at concentrations ranging from 0 to 0.15 mg/L. The equation for the regression line was y = 36.2 + 2.887x (r = 0.9997). Therefore, we found it convenient to calibrate each assay with two standard solutions at 0.075 and 0.15 mgfL, to assay each sample at two different dilutions, and to calculate results by the "slope ratio" method (9). The absence of matrix interference was verified by the convergence of standard and sample dose-response curves at the "zero standard" point.
Detection limit. We analyzed the "zero standard" 18 times to assess the minimum concentration that can be significantly (P <0.01) differentiated from zero. The detection limit was 0.03 mgfL.
Precision and accuracy. To 10 serum samples we added various amounts of teicoplanin to obtain concentrations ranging between 0.094 and 48 mgfL. We then analyzed each sample eight times in different assays by RASA. As shown in Table 1 , the mean analytical recoverywas 99.5% and the between-assayCV was 5.13%. The analytical recoveries of teicoplanin from other biological specimens are reportedin Table 2 . Mean recoveries from ascitic fluid, pleural liquid, homogenates of prostate or skin, and bronchial expectorate range from 98% to 104.8%.
Discussion
Antibodies are used in numerous highly sensitive analytical techniques for detecting antibiotics (10). This type of "analytical reagent" detects the total immunoreactivemate- The use of both types of analytical reagents in the RASA of teicoplanin produces a highly specific assay, as demonstrated by the good analytical recoveries of teicoplanin from various complex matrixes. Moreover, the RASA has a detection limit 16-fold lower than that of a SPERA (3) and half that of microbiological assays (2). This is a marked advantage, particularly when only limited amounts of sample are available, as for specimens from newborn babies.
We conclude that the RASA satisfies the analytical requirements of precision and accuracy for the quantitative detection of teicoplanin in complex matrixes and thus fulifils the need for a more sensitive and selective assay of this antibiotic. However, this assay is more cumbersome than the SPERA, requiring more incubation steps and more CV. % reagents, e.g., the rabbit anti-teicoplarnn antiserum. Thus
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we recommend using this assay to quantify teicoplanin in 2.6 complex matrixes or when a high assay sensitivity is 6 required. Although this assay cannot be used to detect
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glycopeptide antibiotics other than teicoplanin, the same 5 assay design can probably be extended to other compounds 6 of the same class, provided specific antibodies that can form 5. 6 sandwich complexes with the antibiotic and BSA-#{128}-Aca-n-6.7
Ala-n-Ala are available.
